Show simple item record

dc.contributor.authorRochester, Lynn
dc.contributor.authorGalna, Brook
dc.contributor.authorLord, Sue
dc.contributor.authorYarnall, Alison J
dc.contributor.authorMorris, Rosie
dc.contributor.authorDuncan, Gordon
dc.contributor.authorKhoo, Tien K
dc.contributor.authorMollenhauer, Brit
dc.contributor.authorBurn, David J
dc.date.accessioned2017-07-27T05:01:30Z
dc.date.available2017-07-27T05:01:30Z
dc.date.issued2017
dc.identifier.issn0028-3878
dc.identifier.doi10.1212/WNL.0000000000003840
dc.identifier.urihttp://hdl.handle.net/10072/342674
dc.description.abstractObjective: This prospective observational study investigates the role of CSF biomarkers in predicting progression of dopa-resistant gait impairments in Parkinson disease (PD) in the first 36 months from diagnosis. Methods: Quantitative gait analysis was carried out longitudinally using an instrumented walkway (GAITRite) in 108 people with PD and 130 age-matched controls. A subgroup of 44 people with PD underwent lumbar puncture from which a battery of CSF biomarkers was measured: β-amyloid 1–42 and 1–40 (Aβ42 and Aβ40), total and phosphorylated tau protein (t-tau/p-tau181), and α-synuclein (αSyn). Linear mixed models examined the association between CSF and dopa-resistant gait characteristics (defined as substantial progression despite optimal medication). Results: Low baseline CSF Aβ42, and to a lesser extend Aβ40, predicted decline in gait characteristics in the first 3 years following diagnosis, independently explaining up to 12% of progression of step time variability (single task) and step length variability (dual-task). Interestingly, these findings were independent of age and cognition. Conclusions: These findings implicate underlying amyloid pathology in neural networks involved in locomotor control. Results suggest that disturbed Aβ metabolism may be a biomarker for dopa-resistant gait impairments in early PD. Our findings raise interesting questions regarding therapeutic interventions such as compounds or molecules aimed at reducing amyloid burden to mitigate gait disturbance in early PD and potentially falls risk. Finally, progression of discrete gait characteristics suggests they may have potential as clinical biomarkers of pathology and disease progression.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofpagefrom1501
dc.relation.ispartofpageto1511
dc.relation.ispartofissue16
dc.relation.ispartofjournalNeurology
dc.relation.ispartofvolume88
dc.subject.fieldofresearchClinical Sciences not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchCognitive Sciences
dc.subject.fieldofresearchcode110399
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1109
dc.subject.fieldofresearchcode1702
dc.titleDecrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorKhoo, Tien Kheng


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record